SINGAPORE — Stocks in Asia-Pacific nudged higher on Friday as investors reacted to data on China's industrial profits for October.
Markets also scrutinized concerns over the Oxford-AstraZeneca vaccine candidate, with results and methods used in their phase three vaccine trials under criticism from experts in the U.S.
China's industrial profits surged 28.2% year-on-year in October, the country's National Bureau of Statistics announced Friday.
Hong Kong's Hang Seng index was about 0.6% higher, as of its final hour of trading.
Meanwhile, shares in Australia dipped, with the S&P/ASX 200 down by 0.53% on the day to 6,601.10.
MSCI's broadest index of Asia-Pacific shares outside Japan rose 0.24%.
Markets had gotten a boost earlier this week after the interim analysis of clinical trials were released by AstraZeneca. That development had come on the back of a string of encouraging vaccine results after late-stage trial readouts from Pfizer-BioNTech and Moderna, raising hopes of a recovery from the pandemic that has crippled economies globally.
The U.S. dollar index, which tracks the greenback against a basket of its peers, was at 91.919 following its decline earlier this week from levels above 92.4.
The Japanese yen traded at 104.01 per dollar, as compared to an earlier low of 104.28 against the greenback. The Australian dollar changed hands at $0.7378, after rising from levels below $0.732 earlier this week.
— CNBC's Natasha Turak and Sam Meredith contributed to this report.